RNS Number : 3439T
ValiRx PLC
17 July 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

AGM Arrangements

The Company's Annual General Meeting ("AGM") is due to be held on Thursday 23rd July 2020 at 12pm. As set out in the Notice of Annual General Meeting ("Notice") due to the Covid-19 pandemic and associated restrictions on public gatherings, shareholders are encouraged to vote by proxy and not to attend the meeting.

The Board notes that recent legislation permits virtual shareholder meetings to be held during the pandemic and so will arrange for a quorum comprising at least two shareholder-directors to conduct the meeting remotely. Accordingly, under the legislation, the Board intends for the AGM to be held electronically and not in person by the shareholder-directors and so no one will be present at the location identified in the Notice at the appointed time and shareholders are urged not to attend the AGM in person.

The latest date for receipt of proxies is Tuesday 21st July 2020 at 12pm in accordance with the procedure set forth in the Notice. The result of the proxy votes will be announced after the AGM in the usual way. There is also a procedure in the Notice pursuant to which shareholders may ask questions in writing and the Board will respond in due course.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

***** ENDS *****

For more information, please contact:

ValiRx plc	**Tel: +44 (0) 20 7073 2628**
	www.valirx.com
Suzanne Dilly	Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)	**Tel: +44 (0) 20 7213 0880**
Liam Murray / Jo Turner / Ludovico Lazzaretti	
Peterhouse Capital Limited (Sole Broker)	**Tel: +44 (0) 20 7469 0930**

Duncan Vasey / Lucy Williams / Eran Zucker

Notes for Editors

About ValiRx

ValiRx PLC accelerates the development of innovative medicines that enhance patient experience. We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NOAGIGDRDBBDGGR